Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Phase 3 Completed 18 enrolled Kyowa Kirin, Inc.

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of KHK7580 orally administered up to 24 weeks for hypercalcemia in patient with parathyroid carcinoma or primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy.

Timeline

Start: 2017-08-30
Primary completion: 2019-04-09
Completion: 2019-04-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	EVOCALCET	Small molecule	—	Oral

Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism

Summary

Timeline

Drugs

Indications